Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for approximately 85% of cases of lung cancer. The standard first-line therapy for patients without oncogenic driver metastatic NSCLC is anti PD-L1 immune checkpoint inhibition (ICI) with platinum-based chemothe...

Full description

Bibliographic Details

Published in:	Frontiers in oncology Vol. 14; p. 1307882
Main Authors:	Lazar, Raluca, Fischbach, Cathie, Schott, Roland, Somme, Laura
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 27.03.2024
Subjects:	BRAF non-V600E mutations immunotherapy NSCLC Oncology PD-L1 targeted therapy PD-L1 targeted therapy BRAF non-V600E mutations NSCLC immunotherapy
ISSN:	2234-943X, 2234-943X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!